Literature DB >> 26052744

The association between Polycystic Ovary Syndrome (PCOS) and metabolic syndrome: a statistical modelling approach.

S Ranasinha1, A E Joham1,2, R J Norman3, J E Shaw4, S Zoungas1,2, J Boyle1, L Moran1,3, H J Teede1,2.   

Abstract

OBJECTIVE: Polycystic ovary syndrome (PCOS) affects 12-21% of women. Women with PCOS exhibit clustering of metabolic features. We applied rigorous statistical methods to further understand the interplay between PCOS and metabolic features including insulin resistance, obesity and androgen status.
DESIGN: Retrospective cross-sectional analysis. PATIENTS: Women with PCOS attending reproductive endocrine clinics in South Australia for the treatment of PCOS (n = 172). Women without PCOS (controls) in the same Australian region (n = 335) from the Australian Diabetes, Obesity and Lifestyle Study (AusDiab), a national population-based study (age- and BMI-matched within one standard deviation of the PCOS cohort). MEASUREMENTS: The factor structure for metabolic syndrome for women with PCOS and control groups was examined, specifically, the contribution of individual factors to metabolic syndrome and the association of hyperandrogenism with other metabolic factors.
RESULTS: Women with PCOS demonstrated clustering of metabolic features that was not observed in the control group. Metabolic syndrome in the PCOS cohort was strongly represented by obesity (standardized factor loading = 0·95, P < 0·001) and insulin resistance factors (loading = 0·92, P < 0·001) and moderately by blood pressure (loading = 0·62, P < 0·001) and lipid factors (loading = 0·67, P = 0·002). On further analysis, the insulin resistance factor strongly correlated with the obesity (r = 0·70, P < 0·001) and lipid factors (r = 0·68, P < 0·001) and moderately with the blood pressure factor (loading = 0·43, P = 0·002). The hyperandrogenism factor was moderately correlated with the insulin resistance factor (r = 0·38, P < 0·003), but did not correlate with any other metabolic factors.
CONCLUSIONS: PCOS women are more likely to display metabolic clustering in comparison with age- and BMI-matched control women. Obesity and insulin resistance, but not androgens, are independently and most strongly associated with metabolic syndrome in PCOS.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 26052744     DOI: 10.1111/cen.12830

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

1.  Serum Anti-Müllerian Hormone in Polycystic Ovary Syndrome and its Relationship with Insulin Resistance, Lipid Profile and Adiponectin.

Authors:  Thien Jun Jun; Aniza Mohammed Jelani; Julia Omar; Rahimah Abdul Rahim; Najib Majdi Yaacob
Journal:  Indian J Endocrinol Metab       Date:  2020-04-30

2.  Ovulation, a sign of health.

Authors:  Pilar Vigil; Carolina Lyon; Betsi Flores; Hernán Rioseco; Felipe Serrano
Journal:  Linacre Q       Date:  2017-11-27

3.  Efficacy of a Novel Fenugreek Seed Extract (Trigonella foenum-graecum, Furocyst) in Polycystic Ovary Syndrome (PCOS).

Authors:  Anand Swaroop; Amrita Sarkari Jaipuriar; Sushil Kumar Gupta; Manashi Bagchi; Pawan Kumar; Harry G Preuss; Debasis Bagchi
Journal:  Int J Med Sci       Date:  2015-10-03       Impact factor: 3.738

4.  Identification of mRNAs related to endometrium function regulated by lncRNA CD36-005 in rat endometrial stromal cells.

Authors:  Xueying Zhang; Ying Xu; Lulu Fu; Dandan Li; Xiaowei Dai; Lianlian Liu; Jingshun Zhang; Lianwen Zheng; Manhua Cui
Journal:  Reprod Biol Endocrinol       Date:  2018-10-15       Impact factor: 5.211

Review 5.  Metabolic syndrome and its components among women with polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Jamal Hallajzadeh; Maliheh Khoramdad; Nahid Karamzad; Amir Almasi-Hashiani; Ali Janati; Erfan Ayubi; Reza Pakzad; Mark J M Sullman; Saeid Safiri
Journal:  J Cardiovasc Thorac Res       Date:  2018-05-28

6.  The Relationship of Anti-Mullerian Hormone in Polycystic Ovary Syndrome Patients with Different Subgroups.

Authors:  Yu Ran; Qiang Yi; Cong Li
Journal:  Diabetes Metab Syndr Obes       Date:  2021-03-25       Impact factor: 3.168

7.  Assessment of serum chemerin, vaspin and omentin-1 levels in patients with polycystic ovary syndrome.

Authors:  Yesim Guvenc; Ahmet Var; Asli Goker; Naci Kemal Kuscu
Journal:  J Int Med Res       Date:  2016-05-25       Impact factor: 1.671

8.  Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome.

Authors:  Jocelyne Matar Boumosleh; Scott M Grundy; Jennifer Phan; Ian J Neeland; Alice Chang; Gloria Lena Vega
Journal:  J Endocr Soc       Date:  2017-11-02

9.  Correlation of Vitamin D with metabolic parameters in polycystic ovarian syndrome.

Authors:  Arun Kumar; Satish Barki; Vinod Raghav; Ashutosh Chaturvedi; K V S Hari Kumar
Journal:  J Family Med Prim Care       Date:  2017 Jan-Mar

10.  Improving the accuracy and efficacy of diagnosing polycystic ovary syndrome by integrating metabolomics with clinical characteristics: study protocol for a randomized controlled trial.

Authors:  Cheng-Ming Ni; Wen-Long Huang; Yan-Min Jiang; Juan Xu; Ru Duan; Yun-Long Zhu; Xu-Ping Zhu; Xue-Mei Fan; Guo-An Luo; Yi-Ming Wang; Yan-Yu Li; Qing He; Lan Xu
Journal:  Trials       Date:  2020-02-11       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.